CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the epigenetic factors influencing drug resistance in Multiple Myeloma, a type of cancer. By using advanced techniques to analyze patient samples, the aim is to identify specific epigenetic modifiers that can enhance the effectiveness of BCL-2 family inhibitors in treatment.
Multiple Myeloma (MM) is an incurable cancer caused by uncontrolled growth of the plasma cells. A major challenge is drug resistance, which is caused by increased reliance on the anti-apoptotic BCL-2 family proteins and altered epigenetic landscapes.
Dependence is highly variable, with distinct dependencies on BCL-2 family members (MCL-1, BCL-2 & BCL-XL) across patient samples.
It is currently not understood what causes heterogeneity of BCL2 dependence in MM, and thus exploiting this reliance f…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Craigavon
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
